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Implication for health policy/practice/research/medical education:
To detect the occult hepatitis C virus (HCV) infection in Iranian hemodialysis (HD) patients, we examined, 70 anti-HCV neg-
ative HD patients from three dialysis units. Based on the results of  this study, it seems that there is no need for screening of 
HCV-RNA in plasma and peripheral blood mononuclear cells (PBMCs) of  anti-HCV negative hemodialysis subjects.
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Background: Occult hepatitis C virus (HCV) infection is defined as the presence of HCV-
RNA in liver or peripheral blood mononuclear cells (PBMCs) in the absence of detectable 
hepatitis C antibody (anti-HCV) or HCV-RNA in the serum. Low concentrations of HCV-
RNA may be detected in PBMCs of hemodialysis (HD) patients and this could have a great 
impact on the management of HD patients. 
Objectives: The aim of this study was to detect the occult HCV infection in Iranian HD 
patients.
Patients and Methods: A total of 70 anti-HCV negative HD patients from three dialysis units 
in Tehran, Iran were included in this study. In these cases, presence of HCV-RNA in 
plasma samples was tested by reverse transcriptase-nested polymerase chain reaction (RT-
nested PCR). In cases with negative anti-HCV and plasma HCV-RNA, genomic HCV-
RNA was checked in PBMC specimens by RT-nested PCR.
Results: Seventy anti-HCV negative HD patients were enrolled in the study. 32.85% and 
1.43% of cases had elevated levels of alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) respectively. 7.14% of patients had elevated levels of both ALT and 
AST. HCV-RNA was negative in plasma samples of all anti-HCV negative HD subjects. 
The genomic HCV-RNA was not detected in any PBMC samples of HD cases with negative 
anti-HCV and plasma HCV-RNA. 
Conclusions: Occult HCV infection was not detected in our HD patients despite of elevated 
levels of liver enzymes in some participants. Further studies involving larger number of 
HD patients are required to elucidate the rate of occult HCV infection in HD cases. 
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1. Background
Hepatitis C virus (HCV) is a single-strand RNA virus 
(genomic HCV-RNA) with positive polarity that be-
longs to the family flaviviridae and genus hepacivirus. 
Virus replication involves the synthesis of  a comple-
mentary RNA (antigenomic HCV-RNA) that acts as a 
template for production of  genomic HCV-RNA (1,2). 
It is estimated that about 170–200 million people (2% 
of  the world’s population) are infected with HCV (3) 
and its prevalence ranges from 0.2% to 40% in differ-
ent countries (4,5).
A new entity of  HCV infection, occult HCV infec-
tion, was first described in 2004 by Castillo et al (6). 
Occult HCV infection is described as the detection 
of  HCV-RNA in liver or peripheral blood mononu-
clear cells (PBMCs) in the lack of  hepatitis C anti-
body (anti-HCV) or HCV-RNA in the serum (7). It 
has been reported that almost 70% of  patients with 
occult HCV infection have HCV-RNA in their PB-
MCs. Although the most accurate and gold standard 
method for the diagnosis of  occult HCV infection 
is the detection of  HCV genome in the liver, testing 
of  HCV-RNA in PBMCs is an alternative procedure 
when a liver biopsy is not available (8-10). 
Despite screening of  blood products for HCV anti-
body and implementation of  universal infection con-
trol precautions, HCV infection is still a main health 
problem in hemodialysis (HD) patients (8). The prev-
alence of  anti-HCV in HD patients is higher than 
general population, ranging from 7% to 40% (11-13). 
Low concentrations of  HCV-RNA have been detect-
ed in PBMCs of  patients who were cleared HCV ei-
ther spontaneously (14,15) or after treatment (16-18). 
Thus, this could have a great impact on the manage-
ment of  HD patients in dialysis units (19).
 
2. Objectives
To date, only few studies have investigated the pres-
ence of  occult HCV infection in HD patients (8,20-
22). Due to limited data regarding this issue, especially 
in Iranian HD patients, this study was performed to 
determine the existence of  occult HCV infection in 
Iranian HD cases.
3. Patients and Methods
In this cross-sectional study, 70 anti-HCV negative 
HD patients were recruited from three dialysis units 
in Tehran, Iran from March to September 2013. A 
questionnaire was used to collect data such as age, sex 
and length of  time on dialysis. 
All enrolled patients were negative for anti-HCV by 
2 enzyme-linked immunosorbent assays (ELISA) 
(Biorad, Segrate, Italy). 
All of  the cases were also negative for hepatitis B sur-
face antigen (HBsAg) and anti-HIV antibodies.
Liver enzymes (alanin aminotransferase [ALT] and as-
partate aminotransferase [AST]) were also determined 
in all of  the patients using the Hitachi 704 autoanaly-
ser, Tokyo, Japan. The ALT levels above 17 IU/l and 
the AST levels above 24 IU/l were considered as ab-
normal in HD patients (23).
A peripheral blood sample from each patient was col-
lected in an EDTA-containing sterile tube. Plasma 
was separated by centrifugation and stored at –80°C 
for further tests.
The PBMCs were isolated by Ficoll Hypaque (FH) 
gradient centrifugation (Lympholyte-H, Cedarlane, 
Canada). The PBMCs were washed 3 times with 
phosphate-buffered saline (PH = 7.3 ± 0.1). The cells 
were counted and after adding RNAlater (Ambion 
Inc., Austin, TX) solution, were stored at –80°C un-
til examination. Plasma and PBMC specimens from 
10 patients with chronic HCV infection and 10 blood 
donors were used as positive and negative controls, 
respectively. 
3.1. Reverse transcriptase-nested polymerase chain reaction 
(RT-nested PCR) 
RNA was extracted from plasma and a pellet of  about 
3-5×106 PBMC specimens using High Pure Viral Nu-
cleic Acid Kit (Roche Diagnostics GmbH, Mann-
heim, Germany) according to the manufacturer’s in-
structions.
Genomic HCV-RNA in plasma and PBMC specimens 
was detected by RT-nested PCR method. The cDNA 
synthesis and a 2-step PCR with nested primers were 
performed as described previously (24-26). The PCR 
products were electrophoresed in a 1.5% agarose gel 
and stained with ethidium bromide.
The sensitivity of  the PCR amplification method for 
detection of  genomic HCV-RNA was 40 IU/ml plas-
ma. The sensitivity was determined by testing serial 
dilutions of  a plasma specimen with a known viral 
load (determined using Cobas TaqMan 48 Analyzer 
[Roche, Germany]) (26).
3.2. Ethical issues 
1) The research followed the tenets of  the Decla-
ration of  Helsinki; 2) This project was approved by 
the Iranian Society for Support of  Patients with In-
fectious Diseases ethics committee (No. 87) and in-
formed consent was obtained from patients prior to 
their enrollment.
3.3. Statistical analysis
The SPSS 16 package program (Chicago, IL, USA) 
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was used for data analysis. Data are presented as mean 
± SD or, when indicated, as an absolute number and 
percentage. 
4. Results
A total of  70 anti-HCV negative HD patients with 
mean age 58.9 ± 14.7 (range: 24-89) years were en-
rolled in the study. 45.7% of  patients were male and 
54.3% were female. The mean duration of  HD was 
5.9 ± 4.9 years. The mean ALT and AST levels were 
17.7 ± 9.5 (range: 8-71) and 19.1 ± 8.1 (range: 8-56) 
IU/l respectively. 32.85% (23) and 1.43% (1) of  cases 
had elevated levels of  ALT and AST respectively. Five 
(7.14%) patients had elevated levels of  both ALT and 
AST.
HCV-RNA was negative in plasma samples of  all 
anti-HCV negative HD patients. The genomic HCV-
RNA was not detected in any PBMC samples of  HD 
cases with negative anti-HCV and plasma HCV-RNA. 
It means that there was no occult HCV infection in 
our HD subjects.
5. Discussion
In this study the presence of  occult HCV infection 
in Iranian HD patients was determined. The genom-
ic HCV-RNA was not detected in PBMCs of  these 
cases. Our survey showed that occult HCV infection 
was not found in Iranian HD patients despite of  sex, 
age, length of  time on dialysis and aminotransferases 
levels. 
HCV infection is a major cause of  chronic liver dis-
ease and it is diagnosed by the detection of  anti-HCV 
and/or HCV-RNA in serum. In the past years, a new 
entity of  HCV infection was identified and defined as 
occult HCV infection, in which HCV-RNA is unde-
tectable in serum by conventional assays, but patients 
have HCV-RNA in liver or PBMCs (6,27). Occult 
HCV infection is distributed throughout the world 
and all HCV genotypes are involved in this infection. 
Occult HCV infection has been found in different 
high-risk groups for HCV infection such as HD cases 
and family members of  occult HCV patients. It seems 
that this infection is less aggressive than chronic HCV 
infection although patients with occult HCV may de-
velop liver cirrhosis and hepatocellular carcinoma (7). 
Occult HCV infection has been previously investi-
gated in HD patients in few studies. In a survey by 
Barril et al (8) occult HCV infection was found in 
45% of  HD patients with abnormal liver enzyme lev-
els in Spain. These patients had a significantly longer 
time on HD. Thongsawat et al (21) investigated oc-
cult HCV infection during an outbreak in a HD unit 
in Thailand and reported that occult HCV infection 
was common among HD patients in this country. Ri-
nonce et al (22) showed that occult HCV infection 
was detectable in 12.9% of  HD patients in Indone-
sia. They suggested that implementation of  strict in-
fection control programs is necessary in HD units in 
this country. Yakaryilmaz et al (20) reported that the 
prevalence of  occult HCV infection in Turkish HD 
patients was 4.8%.
These differences between the rates of  occult HCV 
infection in dialysis patients may be due to diverse 
prevalence of  HCV infection in different countries 
and within different dialysis units. The overall sero-
prevalence of  HCV infection in the general popula-
tion of  Iran is low and about 0.5% (1.0 in men and 0.1 
in women). The prevalence of  anti-HCV in HD pa-
tients is higher than general population, ranging from 
11%-25% (28). Routine serologic screening of  HCV 
infection, together with strict adherence to universal 
precautions cause to control HCV infection in HD 
patients and decreasing the rate of  HCV infection in 
HD cases (28,29). The overall rate of  HCV infection 
in our three studding HD units was about 6%; so it is 
not unexpected that occult HCV infection was rare in 
our dialysis patients.
As mentioned before, although the detection of  HCV-
RNA in the liver biopsy specimen is the gold stan-
dard method for diagnosis of  occult HCV infection, 
detection of  HCV-RNA in PBMCs is an alternative 
procedure in the absence of  liver biopsy (8,21) and 
HCV-RNA was detected in the PBMCs of  70% of 
patients with occult HCV infection (6,8). Therefore 
detection of  HCV-RNA in PBMCs does not identify 
all cases with occult HCV and because of  liver biopsy 
is not routinely recommended for HD patients, some 
of  the HD cases without HCV-RNA in their PBMCs 
could have occult HCV infection in their liver. There-
fore, it is possible that the rate of  occult HCV infec-
tion in our HD patients was actually higher than those 
reported in this study. 
Occult HCV infection has been described in two dif-
ferent clinical settings: in patients with normal liver 
enzymes (17,18), or in patients with abnormal values 
of  liver enzymes (6,25). In this study we found no oc-
cult HCV infection in our cases despite of  increased 
levels of  liver enzymes in some subjects. 
Some scholars (8,30) reported that duration of  HD 
was significantly longer in patients with occult HCV 
infection, but we did not find this state in our patients. 
6. Conclusions
Occult HCV infection was not detected in our HD 
patients despite of  elevated levels of  liver enzymes 
in some participants. Further studies involving larger 
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number of  HD patients are required to elucidate the 
rate of  occult HCV infection in HD cases. 
7. Limitations of  study
The limitation of  our study is the relatively small sam-
ple size. Therefore, further studies with more cases 
are needed to elucidate the rate of  occult HCV infec-
tion in HD patients.
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